سعر لانجيتينيب 150مجم 30 قرص 2026

Lungitinib 150 mg film-coated tablets (30) by Hikma Specialized Pharmaceuticals (Egypt): erlotinib, an oral EGFR tyrosine kinase inhibitor used in EGFR-mutated non-small cell lung cancer and, with gemcitabine, pancreatic cancer.

• Metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an approved test, for first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen; not recommended in combination with platinum-based chemotherapy.Population: AdultsDailyMed (U.S. National Library of Medicine)
• First-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in NSCLC include rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea and vomiting.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None stated in the label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Interstitial lung disease: withhold for acute onset of new or progressive unexplained pulmonary symptoms; discontinue if ILD is confirmed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Renal failure, hepatotoxicity (with or without hepatic impairment) and gastrointestinal perforation have occurred; monitor and withhold or discontinue as appropriate.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Bullous and exfoliative skin disorders, cerebrovascular accident, microangiopathic hemolytic anemia, ocular disorders and hemorrhage in patients taking warfarin have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitorsAvoid concomitant use if possible; if unavoidable, reduce the erlotinib dose in 50 mg decrements for severe reactions.DailyMed (U.S. National Library of Medicine)
• CYP3A4 inducersAvoid concomitant use if possible; if unavoidable, increase the erlotinib dose in 50 mg increments at about two-week intervals as tolerated.DailyMed (U.S. National Library of Medicine)
• Cigarette smoking / CYP1A2 inducersSmoking reduces erlotinib exposure; patients should stop smoking, and the dose may be increased in 50 mg increments if the patient continues to smoke.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm when administered to a pregnant woman; use effective contraception during treatment and for one month after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Women should not breastfeed during treatment and for 2 weeks after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.